2015 Pharmaceutical Market Trend Vol. I

While the Pharmaceutical Industry has been experiencing many shifts and changes, it is still a 21st Century Growth Industry based on the stats, facts and trends put out by Pharm Exec.More growth expected…

• Basic science of genomics and biology are leading to a discovery of treatments which are advanced by using the body’s own immune system to attack diseases. Auto-immune disorders and oncology disorders have the greatest gains, alongside diagnostic tools which are better so as to make drugs more beneficial to patients.
• Up to 2020, the sales growth for the industry should average 5.1% each year, and the sales worldwide should attain a trillion dollar mark.
• By 2020, Biologic and specialty drugs which require complex protocols for manufacturing should make half of the industry’s sales. Oncology will record the highest growth rate of 10% or more CAGR.
• Most of the profits from the industry will come from oncology and biologic drugs and most probably therapeutic vaccines.
• Currently, the largest company by sales is Novartis, and it is expected to maintain this up to 2020.
• Biotech companies are continuously benefitting from the fact that they are the leading source of innovations, and this has led to an emergence of structuring of capabilities. Big pharma is after being competent in marketing, distribution, global scale and late-stage-development.
• Global health has been encountered to threats, and this has led to underscored in the relevance of the industry in tackling the disease.

What’s Hot

• Out-licensing and Biotech IPOs to big pharma: This year, the volume of the deal is higher. It has involved commercialization rights and asset swaps in multiple markets.
• Reliance on body’s own immune system to treat cancer.
• Use of chemotherapies to attack the growth of tumors.
• New drug combinations which is hot in Oncology.
• An understanding of how the complex procedures of the US ACA will make future drug utilization patterns effective.
• Ensuring patient-adherence to drugs using new IT technologies.
• The virtual sales pitch.
• Finding cost effective and efficient ways to manage the new reporting requirements for medicine promotions.
• Pressure on the “c-suit” to address tighter governance oversight.

What’s Not

• Follow-on medicines in primary care.
• Deploying the field force using the blitzkrieg approach.
• Funding for pre-competitive, basic research.
• Broad-scope patent protection backslash that can be enforced across geographies.
• Big data without the applied analytics that can furnish useful insights on commercial strategy.